The Safety of the Blood Supply — Time to Raise the Bar

Saúde Global

Edward L. Snyder, M.D., Susan L. Stramer, Ph.D., and Richard J. Benjamin, M.D., Ph.D.

DOI: 10.1056/NEJMp1500154

NEJM – Perspective – Existing and emerging pathogens including viruses, bacteria, protozoa, and prions continue to threaten the safety of the blood supply. Blood-collecting facilities, including community and hospital blood banks, have typically relied on a reactive approach to these threats, developing and implementing screening tests after potential pathogens are identified. During this often slow and laborious process, pathogen transmission through transfusion is inevitable. The Food and Drug Administration (FDA) recently approved three new pathogen-reduction technologies (see table).

Pathogen-Reduction Technologies Approved and in Development in the United States and Europe. Pathogen-Reduction Technologies Approved and in Development in the United States and Europe.

These systems are capable of inactivating a wide variety of pathogens in donated blood components, potentially eliminating threats — including some for which no other intervention exists. We believe the FDA should mandate a proactive approach, ensuring ongoing blood safety by requiring treatment of blood…

Ver o post original 1.166 mais palavras

Anúncios

Deixe um comentário

Preencha os seus dados abaixo ou clique em um ícone para log in:

Logotipo do WordPress.com

Você está comentando utilizando sua conta WordPress.com. Sair / Alterar )

Imagem do Twitter

Você está comentando utilizando sua conta Twitter. Sair / Alterar )

Foto do Facebook

Você está comentando utilizando sua conta Facebook. Sair / Alterar )

Foto do Google+

Você está comentando utilizando sua conta Google+. Sair / Alterar )

Conectando a %s